Can blocking the hunger hormone boost weight loss for semaglutide users?

NCT ID NCT07171723

Recruiting now Knowledge-focused Sponsor: University Hospital, Gentofte, Copenhagen Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 30 times

Summary

This study looks at whether blocking the ghrelin (hunger) receptor can further reduce appetite in people with obesity who are already taking semaglutide. About 24 adults on a stable dose of semaglutide will receive either a natural blocker (LEAP2) or a placebo during two study visits. Researchers will measure food intake, hunger feelings, and metabolism to better understand how different appetite systems interact. The goal is to gather knowledge that could lead to better obesity treatments in the future.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY &AMP; OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Center for Clinical Metabolic Research, Gentofte Hospital
RECRUITING

Hellerup, 2900, Denmark

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

OBESITY &AMP; OVERWEIGHT